Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PrimePro + PrimeMSK is a combination stem cell therapy developed by Thomas Advanced Medical. It utilizes mesenchymal stem cells (MSCs) derived from human amniotic and umbilical cord tissues. The therapy is designed to treat a broad spectrum of acute and chronic conditions by leveraging the innate ability of MSCs to home to sites of injury. Once at the target site, these cells secrete a variety of bioactive molecules, including anti-inflammatory cytokines and anti-apoptotic factors, which modulate the immune response and stimulate endogenous tissue repair and regeneration. It is currently being evaluated in a large-scale Phase 1/2 clinical trial (NCT04684602) for indications ranging from musculoskeletal and neurodegenerative diseases to autoimmune and cardiovascular disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PrimePro + PrimeMSK.